Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

Elizabeth R. Plimack,Thomas Powles,Jens Bedke,Frédéric Pouliot,Viktor Stus,Thomas K. Waddell,Rustem Gafanov,Dmitry Nosov,Boris Alekseev,Raymond S. McDermott,Maurice Markus,Sophie Tartas,Anna Kryzhanivska,Igor Bondarenko,Cezary Szczylik,Jianxin Lin,Rodolfo F. Perini,L. Rhoda Molife,Michael B. Atkins,Brian I. Rini

Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

2021

327Background: In the randomized, open-label, phase III KEYNOTE-426 study (NCT02853331), pembrolizumab + axitinib significantly improved overall survival (OS), progression-free survival (PFS), and ...

Keywords:

Oncology
Axitinib
overall survival
Internal medicine
Pembrolizumab
Renal cell carcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations